Drug Treatment

Home/Drug Treatment

Blueprint Medicines Announces Publication in The Lancet Oncology

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.

By |2020-06-30T11:57:14-04:00June 30th, 2020|Ayvakit, Clinical Trials, News|

Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.

By |2020-06-22T09:47:31-04:00June 22nd, 2020|Drug Treatment, News, Qinlock|

QINLOCK (ripretinib) – aprobado como cuarta línea de tratamiento para GIST

La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.

By |2020-06-17T11:29:18-04:00June 17th, 2020|Drug Treatment, Global, News, Qinlock|

LRG Webcast Series: GIST, TKI Treatment & Effects on Memory

This discussion reviewed CRCI in general, and how a person who is being treated for GIST could be affected. We also talked about strategies that can help ameliorate CRCI, new research on CRCI and GIST. we also gave advice on how cancer survivors can best cope with and care for themselves during this unusual global health event.

By |2020-07-20T11:34:41-04:00May 15th, 2020|GIST Education, Gleevec, Webcast|

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST

Blueprint Medicines Does Not Receive Approval from FDA for Avapritinib for Treatment of 4L GIST.

By |2020-05-15T10:10:47-04:00May 15th, 2020|Ayvakit, Clinical Trials, News|

Survival in Advanced GIST Has Improved Over Time – LRG Science

In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.

By |2020-05-01T10:01:32-04:00April 1st, 2020|Drug Treatment, LRG Science, News, Research|

LRG Webcast Series: New Treatment Options for Advanced GIST & Concerns about the Coronavirus

During this webcast presentation, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment and discuss the current coronavirus outbreak.

By |2020-07-09T17:38:29-04:00March 24th, 2020|Drug Treatment, GIST Education, Webcast|

Drug Repository Programs: A Creative Solution

Drug repository programs have the potential to be a key component in accessing life-saving treatments. In a landscape where prices for cancer drugs are escalating, many face a challenge in obtaining life-saving treatments. There are many resources for overcoming these obstacles, but it is clearly not enough for those already struggling with the challenges of a cancer diagnosis.

By |2020-03-04T09:14:56-05:00March 4th, 2020|Drug Treatment, News|

Priority Review Granted for Ripretinib

Deciphera Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for ripretinib for Priority Review. Ripretinib is an investigational broad-spectrum KIT and PDGFRa inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST).

By |2020-02-14T09:57:21-05:00February 14th, 2020|Drug Treatment, News|
Go to Top